UK moves to fast-track coronavirus vaccine if safety tests passed

LONDON (Reuters) - Britain's medical regulator will be able to grant temporary authorisation for any coronavirus vaccine that meets safety and quality standards but before it has received a full licence, under new plans set out on Friday. The government said that under its proposals the Medicines and Healthcare products Regulatory Agency (MHRA) would be able to grant this status to a vaccine while it underwent the full licensing process, with reinforced conditions to ensure safety. The move, described as a last resort in the case of a strong public health justification, means the national regulator will be able to act this year if a vaccine arrives, before Britain has fully left the European Union on Dec

Reuters August 29, 2020 00:12:15 IST
UK moves to fast-track coronavirus vaccine if safety tests passed

coronavirus vaccine if safety tests passed" src="https://images.firstpost.com/wp-content/uploads/reuters/08-2020/29/2020-08-28T170834Z_1_LYNXMPEG7R1FN_RTROPTP_2_HEALTH-CORONAVIRUS-BRITAIN-REGULATOR.jpg" alt="UK moves to fasttrack coronavirus vaccine if safety tests passed" width="300" height="225" />

LONDON (Reuters) - Britain's medical regulator will be able to grant temporary authorisation for any coronavirus vaccine that meets safety and quality standards but before it has received a full licence, under new plans set out on Friday.

The government said that under its proposals the Medicines and Healthcare products Regulatory Agency (MHRA) would be able to grant this status to a vaccine while it underwent the full licensing process, with reinforced conditions to ensure safety.

The move, described as a last resort in the case of a strong public health justification, means the national regulator will be able to act this year if a vaccine arrives, before Britain has fully left the European Union on Dec. 31.

Normally the European Medicines Agency grants a licence for members of the bloc. The MHRA will have a licensing system in place from 2021.

"The proposals consulted on today suggest ways to improve access and ensure as many people are protected from COVID-19 and flu as possible without sacrificing the absolute need to ensure that any vaccine used is both safe and effective," England's Deputy Chief Medical Officer Professor Jonathan Van-Tam said.

The government said it had launched a consultation to discuss the proposals and that it could be in force by October, ahead of the winter flu season. The proposals will also allow more healthcare workers to administer vaccines.

Britain has one of the highest death tolls in the world from COVID-19 and one of the worst economic contractions of any major country.

Like many others, it is pinning its hopes on a vaccine to help bring the pandemic to an end. One of the leading candidates is from the University of Oxford and AstraZeneca, which believes that trial data could go to a regulator this year.

(Reporting by Kate Holton; Editing by Mark Potter)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

Cryptocurrency prices tumble and exchange trading falters as snags crop up
News & Analysis

Cryptocurrency prices tumble and exchange trading falters as snags crop up

NEW YORK (Reuters) -The price of cryptocurrencies plunged and crypto trading was delayed on Tuesday, a day in which El Salvador ran into snags as the first country to adopt bitcoin as legal tender. Shares of blockchain-related firms also fell as crypto stocks were hit by trading platform outages. But the major focus was on El Salvador, where the government had to temporarily unplug a digital wallet to cope with demand.

Ford poaches Apple's car project chief Doug Field
News & Analysis

Ford poaches Apple's car project chief Doug Field

By Joseph White and Sanjana Shivdas (Reuters) -The head of Apple Inc's car project, Doug Field, is going to work for Ford Motor Co to lead the automaker's advanced technology and embedded systems efforts, a hiring coup for Ford Chief Executive Jim Farley.